Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL Jr, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P. Peng W, et al. Among authors: roszik j. Cancer Discov. 2016 Feb;6(2):202-16. doi: 10.1158/2159-8290.CD-15-0283. Epub 2015 Dec 8. Cancer Discov. 2016. PMID: 26645196 Free PMC article.
NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Yoshihama S, Roszik J, Downs I, Meissner TB, Vijayan S, Chapuy B, Sidiq T, Shipp MA, Lizee GA, Kobayashi KS. Yoshihama S, et al. Among authors: roszik j. Proc Natl Acad Sci U S A. 2016 May 24;113(21):5999-6004. doi: 10.1073/pnas.1602069113. Epub 2016 May 9. Proc Natl Acad Sci U S A. 2016. PMID: 27162338 Free PMC article.
Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target.
Alatrash G, Garber HR, Zhang M, Sukhumalchandra P, Qiu Y, Jakher H, Perakis AA, Becker L, Yoo SY, Dwyer KC, Coombes K, Talukder AH, John LSS, Senyukov V, Lee DA, Sergeeva A, He H, Ma Q, Armistead PM, Roszik J, Mittendorf EA, Molldrem JJ, Hawke D, Lizee G, Kornblau SM. Alatrash G, et al. Among authors: roszik j. Leukemia. 2017 Jan;31(1):234-237. doi: 10.1038/leu.2016.249. Epub 2016 Aug 30. Leukemia. 2017. PMID: 27573556 Free PMC article. No abstract available.
SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity.
Park J, Talukder AH, Lim SA, Kim K, Pan K, Melendez B, Bradley SD, Jackson KR, Khalili JS, Wang J, Creasy C, Pan BF, Woodman SE, Bernatchez C, Hawke D, Hwu P, Lee KM, Roszik J, Lizée G, Yee C. Park J, et al. Among authors: roszik j. Cancer Immunol Res. 2017 Aug;5(8):618-629. doi: 10.1158/2326-6066.CIR-17-0051. Epub 2017 Jun 19. Cancer Immunol Res. 2017. PMID: 28630054 Free PMC article.
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes.
Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C, Kuiatse I, Tieu T, Williams L, Devi S, Ashkin E, Xu C, Huang L, Zhang M, Talukder AH, Tripathi SC, Khong H, Satani N, Muller FL, Roszik J, Heffernan T, Allison JP, Lizee G, Hanash SM, Proia D, Amaria R, Davis RE, Hwu P. Mbofung RM, et al. Among authors: roszik j. Nat Commun. 2017 Sep 6;8(1):451. doi: 10.1038/s41467-017-00449-z. Nat Commun. 2017. PMID: 28878208 Free PMC article.
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V. Dembla V, et al. Among authors: roszik j. Sci Rep. 2017 Nov 21;7(1):15963. doi: 10.1038/s41598-017-13114-8. Sci Rep. 2017. PMID: 29162825 Free PMC article.
The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression.
Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets T, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung RM, Wang ZQ, Davis RE, Lo RS, Wargo JA, Davies MA, Bernatchez C, Heffernan T, Amaria RN, Korkut A, Peng W, Roszik J, Lizée G, Woodman SE, Hwu P. Huang L, et al. Among authors: roszik j. Clin Cancer Res. 2018 Jul 15;24(14):3366-3376. doi: 10.1158/1078-0432.CCR-17-2483. Epub 2018 Mar 1. Clin Cancer Res. 2018. PMID: 29496759 Free PMC article.
Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.
Groisberg R, Hong DS, Roszik J, Janku F, Tsimberidou AM, Javle M, Meric-Bernstam F, Subbiah V. Groisberg R, et al. Among authors: roszik j. Mol Cancer Ther. 2018 Jul;17(7):1595-1601. doi: 10.1158/1535-7163.MCT-17-1107. Epub 2018 Apr 13. Mol Cancer Ther. 2018. PMID: 29654067 Free PMC article.
A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma.
Vashisht Gopal YN, Gammon S, Prasad R, Knighton B, Pisaneschi F, Roszik J, Feng N, Johnson S, Pramanik S, Sudderth J, Sui D, Hudgens C, Fischer GM, Deng W, Reuben A, Peng W, Wang J, McQuade JL, Tetzlaff MT, Di Francesco ME, Marszalek J, Piwnica-Worms D, DeBerardinis RJ, Davies MA. Vashisht Gopal YN, et al. Among authors: roszik j. Clin Cancer Res. 2019 Nov 1;25(21):6429-6442. doi: 10.1158/1078-0432.CCR-19-0836. Epub 2019 Aug 22. Clin Cancer Res. 2019. PMID: 31439581 Free PMC article.
177 results